Skip to main content

Table 2 Clinical trials of fourth-generation/next-generation and gene-edited CAR-T cell therapies around the world

From: Recent advances in CAR-T cell engineering

Number Disease Binding epitope Armor/gene-edit Location Start time Study completion Number enrolled Status
NCT04162119 MM BCMA PD-1Fc Sanya, Hainan, China 2019/7/7 2022/10/10 30 Recruiting
NCT04109482 BPDCN,AML,HRMDS CD123 Truncated EGFR Durham, North Carolina, USA 2020/2/25 2026/4/1 126 Recruiting
NCT03778346 MM CD138, integrin β7, CS1, CD38, and BCMA IL7 and CCL19 Lishui, Zhejiang, China 2018/11/15 2022/12/31 30 Recruiting
NCT03929107 B cell lymphoma CD19 IL-7 and CLL 19 Hangzhou, Zhejiang, China 2019/3/28 2022/4/30 80 Recruiting
NCT03258047 B cell lymphoma CD19 PD1/CD28 switch-receptor Hangzhou, Zhejiang, China 2017/9/15 2019/7/30 60 Active, not recruiting
NCT03208556 B cell lymphoma CD19 PD1 shRNA-expressing cassette Beijing, China 2017/6/21 2020/6/1 20 Recruiting
NCT03932955 B cell lymphoma CD19 PD1/CD28 switch-receptor Beijing, China 2019/5/1 2021/5/1 15 Recruiting
NCT04163302 B cell lymphoma CD19 PD-1Fc Sanya, Hainan, China 2019/7/7 2022/7/1 30 Recruiting
NCT03085173 B-CLL CD19 4–1BBL New York, USA 2017/3/15 2020/3/1 37 Recruiting
ChiCTR1900021295 DLBCL CD19 Dominant negative PD1 molecule Shanghai, China 2018/6/1 2022/6/1 5 Not mentioned
NCT03602157 HL CTCL CD30 CCR4 Chapel Hill, North Carolina, USA 2018/12/12 2041/9/30 59 Recruiting
NCT03182816 Advanced solid tumor EGFR CTLA-4/PD-1 antibody Ningbo, Zhejiang, China 2017/6/7 2019/4/20 40 Unknown
NCT02873390 Advanced solid tumor EGFR PD-1 antibody Ningbo, Zhejiang, China 2016/8/1 2018/7/1 20 Unknown
NCT03635632 Neuroblastoma GD2 IL-7 receptors Houston, Texas, USA 2019/4/23 2037/12/1 64 Recruiting
NCT03721068 Neuroblastoma GD2 IL-15 Chapel Hill, North Carolina, USA 2019/2/19 2039/6/19 18 Recruiting
NCT03030001 Advanced solid tumor Mesothelin PD-1 antibody Ningbo, Zhejiang, China 2017/2/15 2019/2/1 40 Unknown
NCT03182803 Advanced solid tumor Mesothelin CTLA-4/PD-1 antibody Ningbo, Zhejiang, China 2017/6/7 2019/4/20 40 Unknown
NCT03615313 Advanced solid tumor Mesothelin PD-1 antibodies Shanghai, China 2018/8/6 2020/12/3 50 Recruiting
NCT03179007 Advanced solid tumor MUC1 Anti-CTLA-4/PD-1 Ningbo, Zhejiang, China 2017/6/7 2019/4/20 40 Unknown
NCT02498912 Advanced solid tumor MUC16 IL-12 New York, USA 2015/8/1 2020/8/1 30 Recruiting
NCT03932565 Advanced solid tumor Nectin4 IL7 and CCL19, or IL12 Zhejiang, China 2019/2/13 2021/12/3 30 Recruiting
NCT04381741 DLBCL CD19 IL7 and CCL19 Zhejiang, China 2020/9/1 2023/9/1 24 Recruiting
NCT03721068 Neuroblastoma GD2 IL-15 North Carolina, USA 2019/2/19 2039/6/19 18 Recruiting
NCT04093648 Hepatoblastoma Glypican 3 IL21 and IL15 United States 2020/1/1 2038/1/1 60 Not yet recruiting
NCT04185038 Central nervous system tumor B7H3 Truncated EGFR Washington, USA 2019/12/11 2041/5/1 70 Recruiting
NCT03208556 B cell lymphoma CD19 PD1 shRNA-expressing cassette Beijing, China 2016/7/1 2019/7/1 20 Recruiting
NCT03198546 Hepatocellular carcinoma GPC3 Soluble TGFβ Guangdong, China 2017/7/1 2022/8/1 30 Recruiting
NCT03706326 Advanced esophageal cancer MUC1 PD-1 Knockout Guangdong, China 2018/9/28 2021/9/28 20 Recruiting
NCT03525782 Non-small cell lung cancer MUC1 PD-1 Knockout Guangdong, China 2018/2/1 2022/1/31 60 Recruiting
NCT03545815 Solid tumor Mesothelin PD-1 Knockout Beijing, China 2018/6/1 2020/6/30 10 Recruiting
NCT03298828 B-ALL and Buekitt lynphoma CD19 PD-1 Knockout Chongqing, china 2017/11/1 2022/10/1 30 Not yet recruiting